Definition
A nominee director is an individual or legal entity instructed by a nominator—such as a shadow director or silent partner—to act on their behalf in the capacity of a director for a legal person. Unlike genuine directors, a nominee director routinely exercises directorial functions according to the nominator’s direct or indirect instructions and is never considered the beneficial owner. This setup is scrutinized in AML contexts because it facilitates anonymity, hindering the identification of ultimate beneficial owners (UBOs) responsible for financial flows.
In AML-specific terms, nominee directors appear on official corporate records but lack substantive decision-making authority, often used in shell companies or offshore entities to mask illicit activities like trade-based laundering or sanctions evasion. FATF explicitly defines them to prevent misuse, emphasizing that they must be disclosed to pierce ownership veils.
Purpose and Regulatory Basis
Nominee directors serve legitimate purposes like privacy for non-resident investors or regulatory residency requirements, but in AML, they matter due to their potential for abuse in concealing UBOs and enabling money laundering/terrorist financing (ML/TF). Their role underscores the need for transparency in corporate governance to mitigate opacity risks.
Key global regulations stem from FATF Recommendation 24 (Transparency and Beneficial Ownership), revised to address nominee arrangements explicitly. Jurisdictions must ensure nominees are not misused, with options like disclosure requirements or prohibitions. In the USA, while the PATRIOT Act enhances due diligence on corporate transparency (Section 312 for private banking), broader Corporate Transparency Act (CTA) mandates BO reporting, treating nominees as red flags requiring verification. EU AML Directives (AMLD5/AMLD6) demand identification of beneficial owners beyond 25% thresholds, with enhanced scrutiny for nominees in high-risk structures. National implementations include Singapore’s CSP Act requiring nominee status disclosure to ACRA and New Zealand’s mandates for CDD on nominators.
When and How it Applies
Nominee directors apply during corporate onboarding, account openings, or transactions involving entities with apparent non-resident directors or rapid directorship changes. Triggers include incomplete BO declarations, nominees linked to multiple shells, or funds from high-risk jurisdictions.
Real-world use cases: A nominee registers an offshore company receiving disguised trade payments, then repatriates “clean” funds—prompting SARs if patterns emerge. In scam networks, nominees front shelf companies for fraud, shielding criminals from KYC. Financial institutions apply EDD by verifying nominee status and nominator identity upon suspicion or routine screening.
Types or Variants
Nominee directors include resident nominees fulfilling local directorship rules (e.g., one local director in Singapore) while acting per instructions. “Silent” or “shadow” directors provide a name but no oversight, common in high-risk setups.
Variants: Professional nominees from Corporate Service Providers (CSPs), requiring fit-and-proper checks; Straw directors in virtual companies with no real control; Nominee general partners in partnerships. Examples: UK TCSP-registered nominees for non-residents, banned as PSCs under PSC regime.
Procedures and Implementation
Institutions comply via risk-based AML programs integrated with CDD/EDD processes.
- Screen for nominee indicators using watchlists, PEP databases, and BO registries during onboarding.
- Obtain declarations confirming nominee status, nominator IDs (passports, proofs), source-of-wealth, and purpose.
- Implement transaction monitoring for anomalies like unusual volumes or high-risk links.
- Deploy AML software for ongoing surveillance; conduct annual BO recertification.
- Train staff on red flags; maintain audit trails.
For appointment (e.g., India Companies Act): Board resolution, DIN application, DIR-12 filing within 30 days.
Impact on Customers/Clients
Customers using nominee directors face rights to privacy but restrictions like mandatory disclosures to institutions. They must provide nominator details, risking account suspension if uncooperative.
Interactions involve EDD requests; non-compliance leads to service denial or reporting. From a client view, legitimate use enhances compliance (e.g., via regulated CSPs), but misuse exposes them to investigations, frozen assets, or director disqualification.
Duration, Review, and Resolution
Nominee appointments last per agreement but require ongoing review: annual recertification or event-triggered (e.g., ownership changes). Timeframes: Updates within 2 business days in Singapore; 30 days for filings like DIR-12.
Review processes: Internal audits, regulatory inspections simulating checks. Resolution: Remove nominee if risks escalate, update BO registers, or terminate relationship. Ongoing obligations include monitoring for control shifts.
Reporting and Compliance Duties
Institutions document all nominee interactions, retaining records 5-10 years per BSA/AMLD. File SARs within 30 days for suspicions via FinCEN/FIUs.
Duties: Disclose status publicly (e.g., Singapore ACRA); CSPs perform fit-and-proper assessments. Penalties: Fines >USD 1M (e.g., HSBC), imprisonment (Singapore: 4-10 months for silent directors), license revocation.
Related AML Terms
Nominee directors connect to Ultimate Beneficial Owner (UBO)—nominees never qualify as UBOs, requiring nominator identification.[web://11] Linked to shell companies, where nominees mask ownership; Persons with Significant Control (PSC) regimes excluding nominees.
Other terms: Nominee shareholders (voting per instructions); Corporate Service Providers (CSPs) facilitating arrangements. Ties to EDD, red flags like layered structures, and FATF R10/24 on transparency.
Challenges and Best Practices
Challenges: Defining “nominee” varies (narrow FATF vs. broader national); opacity in multi-jurisdictional setups; “silent” director negligence leading to liability.
Best practices: Use regulated CSPs; rigorous KYC on nominators; periodic risk assessments and governance reviews. Train on FATF options; integrate with BO registers; simulate audits. Avoid PSC misuse; ensure active oversight.
Recent Developments
2024-2025 FATF R24 revisions mandate nominee disclosures, adopted in Singapore (CSP Act 2025: central filings by Dec 2025, imprisonment default). Singapore High Court (2025) stiffened sentences for silent directors.
EU AMLR/AMLA (2024+) lowers BO thresholds to 15% for risks, enhances digital registers. Bermuda/Singapore require status reporting over bans. UK emphasizes AML-registered providers; global crackdown on misuse via CTA equivalents.